CLAIM #30470 · Honeywell International Inc (HON) · 2025Q1 earnings call · Apr 29, 2025 · due Dec 31, 2025
“Based on tariffs in place today, our approximate 2025 exposure is about $500 million before taking any mitigation measures.”
Vimal Kapur · CEO
In context
“ns and performing admirably well, with the bulk of integration work behind us, reinforcing that we have the right M&A process in place to create incremental value. While we continue to evaluate acquisitions, we also look forward to opportunistically exiting businesses such as personal protective equipment that do not fit into our business model or strategic priorities. The PPE sale will improve margins and organic growth. I will now move to slide six to address how we view the present global uncertainty. As a company, we remain confident in our ability to navigate the current trade environment. For decades, we have positioned each of our business lines to serve their local markets. This local-for-local strategy reduces our overall exposure to international trade and geopolitical tensions. Based on tariffs in place today, our approximate 2025 exposure is about $500 million before taking any mitigation measures. Our better-tested accelerated operating system can quickly identify areas of concern and implement mitigation efforts. Then we pursue consistent and clear communication with our suppliers, customers, and partners to maximize operational stability for all parties. Through this well-developed operational system and our established local-for-local footprint, we are confident we can fully offset the impact of current tariffs and are well-positioned to manage future trade uncertainty. This is evident in today's results, and our confidence in maintaining and raising guidance is part of these offsetting headwinds. Most importantly, whenever elevated global tensions do subside, we remain in an excellent position to capitalize on record backlog and continue our growth trajectory. Now let me turn o”
Verify independently
SEC filings for HON ↗ · Claim quote is verbatim from the 2025Q1 earnings call.